Knowthestock.com
GILD - Gilead Sciences, Inc.
SNP 500NASDAQ

Sell

Moderate Growth but Declining
WeakStrong
WeakStrong

47%

based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 3.31%
Operating Income Growth is -90.05%
Net Income Growth is -97.86%
Earnings Per Share (EPS) Growth is -98.28%
Net Margin is 0.45%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.26
Debt Ratio is 0.24
Current Debt to Net Income Ratio is 1.45
Total Debt to Total Assets Ratio is 0.46
Cash Flow is STRONG
Cash from Operations Growth is 19.25%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Gilead Sciences, Inc. (GILD) - www.gilead.com
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative to community organizations that are working to combat HIV in the Southern United States. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.
Exchange - NASDAQ
Industry - Biological Product (except Diagnostic) Manufacturing
Sector - Manufacturing
CEO - Daniel O'Day
Employees - 17,000
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.